Diagnostic challenge of identifying cases with recurrent t(8;14)(q24.21;q32.2) Involving BCL11B in acute leukemias of ambiguous lineage: an analysis of eight patients

2021 ◽  
pp. 1-4
Author(s):  
Sonja Bendig ◽  
Anna Stengel ◽  
Wencke Walter ◽  
Manja Meggendorfer ◽  
Constance Baer ◽  
...  
Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 5191-5191
Author(s):  
Gustavo Henrique de Medeiros Oliveira ◽  
Lenilton Silva DA Silva Júnior ◽  
Antonia Eduarda Martins Oliveira Elói Silva ◽  
João Pedro Andrade Lima ◽  
Victor lima Soares ◽  
...  

INTRUDUCTION: Acute myeloid leukemia (AML) is a heterogeneous group of clonal disease of hematopoietic tissue, characterized by proliferation of abnormal myeloid progenitor cells, suppressing the normal hematopoietic activity and constituting a great diagnostic challenge. With the advent of immunophenotyping by flow cytometry, the diagnosis of these neoplasms became more faithful, facilitating the treatment and follow-up of the patients. METHODS: In this study a flow cytometric immunophenotyping study was performed in bone marrow aspirate and / or peripheral blood samples from 38 patients with AML, using a panel of monoclonal antibodies specific for acute leukemias, also investigating clinical, laboratory and demographic data of these patients. RESULTS AND DISCUSSION: Of the 38 subjects studied, 23 were male and 15 females. In relation to the age, we found a higher number of cases in adult patients. According to clinical data, splenomegaly and hepatomegaly were present in most cases. The immunophenotyping demonstrated a characteristic profile of AML with expression of CD13 and CD33 in all cases and CD34 and CD117 in most cases. The CD14 was reactive in monocytic leukemia (M4 and M5-AML). Were observed negativity for lymphoid antigens CD19, CD10 and CD3 and positivity to CD7, CD56 and CD2, present in 10, 5 and one cases respectively. Regarding cytomorphology, there was a direct correlation with FAB classification, with the prevalence of type myeloid-monocytic (AML-M4). CONCLUSION: These data demonstrate the importance of immunophenotyping in the differential diagnosis of AML and monitoring of these neoplasms. Disclosures No relevant conflicts of interest to declare.


2019 ◽  
Vol 493 ◽  
pp. S253-S254
Author(s):  
C. Pizarro Sánchez ◽  
L.A. Bautista Balbás ◽  
M. Rodríguez Gutiérrez ◽  
M. Morado Arias ◽  
A.L. Qasem Moreno ◽  
...  

2018 ◽  
Vol 24 ◽  
pp. 199
Author(s):  
Mumtaheena Miah ◽  
Puspalatha Sajja ◽  
Catherine Anastasopoulou ◽  
Nissa Blocher ◽  
Janna Prater

2021 ◽  
Vol 36 ◽  
pp. 8-10
Author(s):  
Mette Louise Halck
Keyword(s):  

2019 ◽  
Vol 10 (04) ◽  
pp. 158-160
Author(s):  
Ulrike Röper

Weiterentwicklungen in der Molekulardiagnostik ermöglichen zuverlässigere Aussagen zur Differenzialdiagnostik maligner Erkrankungen. Sie sind Meilensteine für eine individualisierte Therapie. Darüber hinaus zeigt sich ihre zunehmende Bedeutung für prognostische Einschätzungen. Die Kontrolle der minimalen Resterkrankung (Minimal Residual Disease; MRD) rückt zunehmend in den Fokus, auch wenn noch viele Fragen zu klären sind.


2019 ◽  
Vol 10 (03) ◽  
pp. 120-122
Author(s):  
Beate Fessler

Die akute myeloische Leukämie (AML) hat nach wie vor eine schlechte Prognose. Das könnte sich mit der Entwicklung zielgerichteter Therapien bald ändern. Auf dem internationalen Symposium „Acute Leukemias XVII“ wurden neue vielversprechende Optionen für Patienten mit AML vorgestellt, die zielgenau eingesetzt werden. Interessant sind vor allem Kombinationstherapien.


2015 ◽  
Vol 122 (03) ◽  
Author(s):  
IA Vasilakis ◽  
A Koerner ◽  
M Preuß ◽  
FW Hirsch ◽  
J Kratzsch ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document